Loading News...
Back to Dashboard

Veradermics, Incorporated (MANE)

Real-time intraday values

Market Overview

From:
To:
MANE Intraday
No data available
SymbolMANE
IPO DateFeb 4, 2026
CEODr. Reid Waldman M.D.
Full Time Employees37
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNYSE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Performance
PeriodReturn %Value Change
1 Day
+12.36%
+13.45 US$
5 Days
+7.75%
+8.79 US$
1 Month
+14.53%
+15.52 US$
6 Months
+73.89%
+51.96 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of MANE...

Key Statistics
Market Cap
5.11B
P/E Ratio
N/A
Div Yield
0.00%
52W High
$136.72
52W Low
$32.00

Analyst Consensus

ConsensusStrong Buy
Bullish7100.0%
Neutral00.0%
Bearish00.0%

52W Analyst Price Targets

Min Target
$135.00
Max Target
$182.00
Current$122.27
Avg Target$164.83

Analyst Recommendations

Target Price:$164.83($135.00 - $182.00)
FirmRatingTarget PriceUpside PotentialDate
Cantor FitzgeraldOverweight$0.00-100.00%10/19/2026
NeedhamBuy$172.00+40.68%10/19/2026
CitigroupBuy$160.00+30.86%7/16/2026
NeedhamBuy$164.00+34.13%7/15/2026
B. Riley SecuritiesBuy$170.00+39.04%7/15/2026
JefferiesBuy$182.00+48.86%7/7/2026
LifeSci CapitalOutperform$135.00+10.42%6/16/2026
NeedhamBuy$136.00+11.23%6/2/2026
CitigroupBuy$135.00+10.42%5/18/2026
Leerink PartnersOutperform$90.00-26.39%4/22/2026
Community Thoughts

Share your analysis and sentiment on MANE

Join the community to share your analysis